Triterpenoid for inhibiting novel coronavirus olmitron mutant strain and novel pharmaceutical application of triterpenoid
Through the discovery and application of glycepacic acid, the problem of insufficient inhibitory effect on the novel coronavirus mutant Aomimilon cloning and other types was solved, and effective inhibition and prevention of novel coronavirus mutants was achieved, and important clinical application value was achieved.
Patent Information
- Application Number
- CN202310628159.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-31
- Publication Date
- 2024-12-03
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Existing anti-novel coronavirus drugs have limited inhibitory effects on mutants such as Omiclone, and there is a lack of effective drugs to prevent and treat novel coronavirus mutants that cause human infection.
As a triterpene compound, glycepacic acid has a significant inhibitory effect on the receptor binding region (RBD) of the current mainstream strain of the novel coronavirus, BA.4/XBB/BQ1.1, for the preparation of prevention and Drugs for treating novel coronavirus mutants and other coronavirus infections.
Gampanic acid significantly inhibits RBD of the novel coronavirus mutant, provides a new antiviral pathway, has potential clinical application prospects, and can effectively prevent and treat novel coronavirus infection.
Smart Images

Figure CN119055658A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to a new pharmaceutical application of the triterpene compound carbenoxolone, and specifically to an application of carbenoxolone in an inhibitory drug for a novel coronavirus mutant, Omiclon. Background Art
[0003] The genome of SARS-CoV-2 can encode four structural proteins: spike protein S, envelope protein E, membrane protein M and nucleocapsid protein N. Among them, S protein is a trimeric class I viral fusion protein that interacts with angiotensin 2 (ACE2) receptors through its receptor binding region (RBD), thereby mediating the entry of the virus into human host cells. Therefore, S protein is a key target for preventing viral infection, and the RBD region is the key binding site of S protein (Laurini E et al., ACS Nano 2020, 14, 11821-11830). S protein and ACE2 have received widespread attention in the screening of viral inhibitors, involving multiple mechanisms. For example, rhein, forsythiaside A, forsythiaside I, neochlorogenic acid, etc., bind to ACE2 and block the binding of S protein to play an antiviral role (Chen X et al. Acta Pharmaceutica Sinica B 2020, 11, 222-236). Danshen acid C can bind to the S2 subunit of the S protein, preventing the formation of its six-helix bundle structure, thereby inhibiting the fusion of the viral membrane and the cell membrane (Liu SW et al., Signal Transduction and Targeted Therapy 2020, 5, 220).
[0004] Licorice (Glycyrrhizae Radix et Rhizoma) is a commonly used traditional Chinese medicine with antiviral pharmacological activity. Recently, studies have found that the triterpenoid compounds glycyrrhetinic acid and glycyrrhizin A3 in licorice can inhibit the S protein of the new coronavirus, and have strong anti-new coronavirus activity at the cellular level. 50 3.17μM and 75nM respectively (Yang Y et al., J Adv.Res.2022, 36, 201-210). Carbenoxolone is a glycyrrhetinic acid analogue and is clinically used for peptic ulcers. This study found that carbenoxolone has a significant inhibitory effect on the RBD of the current mainstream strain of the new coronavirus, Omicron BA.4 / XBB / BQ1.1. Given that sodium carbenoxolone is a commonly used clinical drug and its anti-new coronavirus activity has not been reported. Therefore, the present invention proposes a new drug use of carbenoxolone against new coronavirus mutants, which has important practical significance and good clinical application prospects for future resistance to new coronavirus mutants or other coronaviruses that endanger human health. Summary of the invention
[0005] The purpose of the present invention is to provide a drug for preventing and / or treating novel coronavirus mutants and future highly harmful coronaviruses.
[0006] Through research, the present invention found that carbenoxolone has a significant inhibitory effect on the RBD of the current mainstream strain of the new coronavirus, Omicron BA.4 / XBB / BQ1.1, thereby providing a new pathway for the new coronavirus mutants and other coronaviruses that may cause human infection in the future.
[0007] The structural formula of carbenoxolone is as follows:
[0008]
[0009] The carbenoxolone described in the present invention is a triterpenoid compound. The compound itself or at least one of its pharmaceutically acceptable salts, esters, solvates, stereoisomers, tautomers, prodrugs, and mixtures thereof can inhibit the novel coronavirus mutant Omicron BA.4 / XBB / BQ1.1RBD, and can be used to prevent and / or treat infection by the novel coronavirus mutant and other coronaviruses that may cause human infection in the future.
[0010] Drugs for preventing and / or treating coronavirus infection prepared with the above-mentioned active compounds or their pharmaceutically acceptable salts, esters, solvates, stereoisomers, tautomers, prodrugs and mixtures thereof as active ingredients also fall within the scope of protection of the present invention.
[0011] When necessary, one or more pharmaceutically acceptable carriers or excipients may be added to the above-mentioned drugs. The carriers or excipients include conventional diluents, excipients, fillers, binders, wetting agents, disintegrants, absorption promoters, surfactants, adsorption carriers, lubricants, etc. in the pharmaceutical field.
[0012] The above active compounds or their pharmaceutically acceptable salts, esters, solvates, stereoisomers, tautomers and prodrugs are used as active ingredients, alone or in combination, or in combination with other drugs, excipients, etc. to prepare various dosage forms, including but not limited to tablets, powders, pills, injections, capsules, films, suppositories, ointments, granules, etc. The above various dosage forms of drugs can be prepared according to conventional methods in the pharmaceutical field.
[0013] The carbenoxolone provided by the present invention is a triterpene compound, which is mainly used in the clinic to treat chronic gastric ulcers, and its anti-new coronavirus activity has not been reported. The present invention first discovered that carbenoxolone has a significant inhibitory effect on the RBD of the current mainstream strain of the new coronavirus OmicronBA.4 / XBB / BQ1.1, thereby exerting antiviral activity, and can be used to prepare drugs or health products for treating and / or preventing new coronavirus mutants that cause human infection, as well as coronaviruses that will appear in the future. BRIEF DESCRIPTION OF THE DRAWINGS
[0014] Figure 1 The results of the experiment for detecting the affinity of carbenoxolone for SARS-CoV-2 RBD in Example 1 are shown.
[0015] Figure 2 The results of the experiment for detecting the affinity of carbenoxolone to SARS-CoV-2 Omicron BA.4 RBD in Example 1 are as follows.
[0016] Figure 3 The results of the experiment to detect the affinity of carbenoxolone to SARS-CoV-2 Omicron XBB RBD in Example 1.
[0017] Figure 4 The results of the experiment to detect the affinity of carbenoxolone to SARS-CoV-2 Omicron BQ1.1 RBD in Example 1.
[0018] Figure 5 The results of the experiment for detecting the inhibition rate of carbenoxolone on SARS-CoV-2 RBD in Example 2 are as follows.
[0019] Figure 6 The results of the experiment for detecting the inhibition rate of carbenoxolone on SARS-CoV-2 Omicron BA.4 RBD in Example 2 are as follows.
[0020] Figure 7 The results of the experiment for detecting the inhibition rate of carbenoxolone on SARS-CoV-2 Omicron XBB RBD in Example 2 are as follows.
[0021] Figure 8 The results of the experiment for detecting the inhibition rate of carbenoxolone on SARS-CoV-2 Omicron BQ1.1 RBD in Example 2 are as follows.
[0022] Fig. 9 The experimental results of Example 3 are for detecting the viral inhibition rate of carbenoxolone on SARS-CoV-2 virus infection of Vero E6 cells.
[0023] Fig.10The experimental results of Example 3 are for detecting the viral inhibition rate of carbenoxolone on SARS-CoV-2 Omicron BA.5 virus-infected Vero E6 cells. DETAILED DESCRIPTION
[0024] The present invention is further described below in conjunction with examples. It should be understood that the following examples are only used to illustrate the present invention and are not used to limit the scope of protection of the present invention.
[0025] Unless otherwise specified, the experimental methods used in the following examples are conventional methods.
[0026] Unless otherwise specified, the materials and reagents used in the following examples can be obtained from commercial sources.
[0027] Example 1. Affinity detection of carbenoxolone for the new coronavirus and its mutant Omicron BA.4 / XBB / BQ1.1 RBD.
[0028] 1. Experimental materials and methods.
[0029] For different spike proteins, amino coupling kits were used to fix them on the CM5 chip. The S protein was diluted with 10mM sodium acetate buffer (pH=4.5) to a final concentration of 30μg / mL and fixed with PBS-T. The protein coupling value was about ~9000RU. Inhibitor small molecules of different concentrations were dissolved in buffer (PBS containing 5% DMSO and 0.05% T20) and diluted from 100μM to 10 concentrations. The buffer flow rate was 30μL / min, the binding time was 60s, and the dissociation time was 60s. Biacore software was used to fit and calculate the equilibrium dissociation constant K of protein-ligand binding. D The SPR instrument used was Biacore 8K.
[0030] 2. Experimental results.
[0031] Plasmon resonance results showed that carbenoxolone has affinity for SARS-CoV-2 RBD, K D =94.2μM, SARS-CoV-2Omicron BA.1 RBD, K D =39.2μM, SARS-CoV-2 Omicron XBB RBD, K D =5.70μM, SARS-CoV-2Omicron BQ1.1 RBD, K D =5.80μM, such as Figure 1 , 2 , 3, and 4.
[0032] Example 2: Detection of the inhibition rate of carbenoxolone on the new coronavirus and its mutant Omicron BA.4 / XBB / BQ1.1 RBD.
[0033] 1. Experimental materials and methods.
[0034] The screening of S-RBD protein inhibitors uses enzyme-linked immunosorbent assay (ELISA) (Diagnostics 2021, 11, 271). This method is commonly used to detect RBD antibodies and is rarely used for small molecule detection. The present invention optimizes the system specifically for the screening of small molecule inhibitors. The solid surface of the 96-well ELISA plate is coated with S protein (0.5 μg / mL), and the coating solution uses Na2CO3-NaHCO3 (pH 9.6). Incubate overnight at 4°C and wash (the washing solution is PBS containing 0.05% Tween 20, the same below). Add 2% BSA to block for 40 minutes and wash. Add compounds (at a concentration gradient of 80, 40, 20, 10, 5, 2.5 μM) and incubate, wash. Add ACE2 protein (0.5 μg / mL) that can be linked to HRP, incubate for 1 hour, and wash. ACE2 protein and candidate compounds are dissolved in PBS and diluted with 1% BSA. Add enzyme-linked antibody SA-HRP (1:15000), incubate for 1 hour, wash, add TMB for color development, and after 5 minutes, add 1M hydrochloric acid as a stop solution, and detect at OD 450nm with a microplate reader.
[0035] 2. Experimental results.
[0036] Carbenoxolone inhibits SARS-CoV-2 RBD, IC 50 The values were 10.60±3.14μM, SARS-CoV-2Omicron BA.4 RBD, IC 50 The values were 2.50±0.37μM, SARS-CoV-2 Omicron XBB RBD, IC 50 The values were 10.02±1.38μM, SARS-CoV-2 Omicron BQ1.1 RBD, IC 50 The values were 9.09±0.33μM, Figure 5 , 6 , 7, and 8.
[0037] Example 3: Detection of the viral inhibition rate of carbenoxolone on SARS-CoV-2 wild-type and mutant Omicron BA.2 viruses infecting Vero E6 cells
[0038] 1. Experimental Materials and Methods
[0039] To detect the inhibitory activity of carbenoxolone on virus entry into cells, Vero E6 cells (40,000 cells / well) were inoculated in a 48-well plate, and carbenoxolone (gradient of 40, 10, 3, 1, 0.3 μM) was added with SARS-CoV-2 wild-type and mutant OmicronBA.5 virus liquid (MOI = 0.1). After mixing and culturing for 24 hours, RNA was extracted using an RNA extraction kit (52906, Qiagen) and then quantitatively detected.
[0040] 2. Experimental Results
[0041] Carbenoxolone can inhibit SARS-CoV-2 virus infection, EC 50 4.223μM, inhibiting SARS-CoV-2 OmcironBA.2 virus infection, EC 50 is 10.29 μM, such as Fig. 9 , 10 shown.
Claims
1. Use of at least one of carbenoxolone and its pharmaceutically acceptable salts, esters, solvates, stereoisomers, tautomers, and prodrugs in the preparation of drugs or health products for preventing and / or treating novel coronavirus, novel coronavirus mutants BA.4 / XBB / BQ1.1, and other coronavirus infections, wherein: The structural formula of the carbenoxolone is shown below:
2. The use according to claim 1, characterized in that The novel coronavirus, the novel coronavirus mutant Omicron BA.4 / XBB / BQ1.1, and other coronaviruses that may cause human infection in the future.
3. A medicine or health product for preventing and / or treating infection with the novel coronavirus or novel coronavirus mutant Omicron BA.4 / XBB / BQ1.1, comprising at least one of carbenoxolone and its pharmaceutically acceptable salts, esters, solvates, stereoisomers, tautomers, and prodrugs as an active ingredient, wherein the structural formula of carbenoxolone is as follows:
4. The medicine or health product according to claim 3, characterized in that The coronavirus described is the new coronavirus, the new coronavirus mutant Omicron BA.4 / XBB / BQ1.1, and other coronaviruses that may cause human infection in the future.
5. The medicine or health product according to claim 3, characterized in that: The medicine or health product further contains one or more pharmaceutically acceptable carriers or excipients.
6. Use of at least one of carbenoxolone and its pharmaceutically acceptable salts, esters, solvates, stereoisomers, tautomers, and prodrugs as an inhibitor of coronavirus spike protein, wherein: The structural formula of the carbenoxolone is shown below:
7. The use according to claim 6, characterized in that The coronavirus spike protein is the novel coronavirus, the novel coronavirus mutant Omicron BA.4 / XBB / BQ1.1, and other coronavirus spike proteins that may cause human infection in the future.
Citation Information
Patent Citations
Inhibition of glycyrrhizin A3 on novel coronavirus spike protein and medicinal application of glycyrrhizin A3
CN115192590A
